Treatment News : Lawmakers Attack High Price of Gilead's Hep C Drug Sovaldi

POZ - Health, Life and HIV
Subscribe to:
POZ magazine
E-newsletters
Join POZ: Facebook MySpace Twitter Pinterest
Tumblr Google+ Flickr MySpace
POZ Personals
Sign In / Join
Username:
Password:

Back to home » Treatment News » March 2014

Most Popular Links
Most Popular Lessons

The HIV Life Cycle

Shingles

Herpes Simplex Virus

Syphilis & Neurosyphilis

Treatments for Opportunistic Infections (OIs)

What is AIDS & HIV?

Hepatitis & HIV

15 Years Ago In POZ


More Treatment News

Click here for more news

Have news about HIV? Send press releases, news tips and other announcements to news@poz.com.


emailprint

March 25, 2014

Lawmakers Attack High Price of Gilead's Hep C Drug Sovaldi

Three Democratic members of the House Energy and Commerce Committee have sent a letter to Gilead Sciences demanding it justify the price of its recently approved hepatitis C drug, Sovaldi (sofosbuvir).

The Food and Drug Administration approved the hep C med for use in people who also have HIV, making it the first FDA-backed treatment for coinfection.

In the letter, ranking members Henry A. Waxman, Frank Pallone Jr. and Diana DeGette said they were responding to reports indicating that the pharmaceutical company intends to sell the drug at $84,000 per treatment, or up to $1,000 per pill.

They said that the prices are likely too high for many hep C patients with public and private health insurance, which will ultimately impede the treatment of the disease. The letter cites the fact that many state Medicaid programs are already seeking to limit the public’s use of the new drug and that in places that do cover it, people with employer or individual coverage may have to make up these costs with more taxes and potential premium increases.

The committee is now requesting a full brief on the methodology used by Gilead to price Sovaldi, the extent to which the company plans to provide discounts for the drug, and the public health impact of insurers’ decisions not to cover the medication for all patients with hepatitis C virus (HCV).

They are asking Gilead to provide this briefing to the public no later than April 3, 2014.

To read the letter, click here.

Search: Gilead, Sovaldi, House Energy and Commerce Committee, high cost, attack, hepatitis C, HCV, coinfection, Henry A. Waxman, Frank Pallone Jr., Diana DeGette, price briefing


Scroll down to comment on this story.



Name:

(will display; 2-50 characters)

Email:

(will NOT display)

City:

(will display; optional)

Comment (500 characters left):

(Note: The POZ team reviews all comments before they are posted. Please do not include either ":" or "@" in your comment. The opinions expressed by people providing comments are theirs alone. They do not necessarily reflect the opinions of Smart + Strong, which is not responsible for the accuracy of any of the information supplied by people providing comments.)

Comments require captcha.
Please enter this number for verification:

| Posting Rules



Show comments (0 total)

 
[Go to top]


Join POZ Facebook Twitter Google+ MySpace YouTube Tumblr Flickr
Quick Links
Current Issue

HIV Testing
Safer Sex
Find a Date
Newly Diagnosed
HIV 101
Disclosing Your Status
Starting Treatment
Help Paying for Meds
Search for the Cure
POZ Stories
POZ Opinion
POZ Exclusives
Read the Blogs
Visit the Forums
Job Listings
Events Calendar


    CuteBoyinQns
    Jackson Heights
    New York


    Poz_Qt
    Columbus
    Ohio


    Deelight4u
    BROOKLYN
    New York


    josebos
    Boston strong
    Massachusetts
Click here to join POZ Personals!
Ask POZ Pharmacist

Talk to Us
Poll
Will decriminalizing injection drug use help end the global HIV epidemic?
Yes
No

Survey
PrEP Course

more surveys
Contact Us
We welcome your comments!
[ about Smart + Strong | about POZ | POZ advisory board | partner links | advertising policy | advertise/contact us | site map]
© 2014 Smart + Strong. All Rights Reserved. Terms of use and Your privacy.
Smart + Strong® is a registered trademark of CDM Publishing, LLC.